Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alnylam Pharmaceuticals
(NQ:
ALNY
)
152.33
+2.02 (+1.34%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Alnylam Pharmaceuticals
< Previous
1
2
3
4
5
Next >
3 Stocks to Buy For the COVID Resurgence
September 06, 2023
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting
Via
MarketBeat
Exposures
COVID-19
Product Safety
Alnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against Moderna
August 25, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
August 03, 2023
From
Alnylam Pharmaceuticals
Via
Business Wire
Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference
August 02, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
July 24, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Conference Call Discussing Second Quarter 2023 Financial Results
July 20, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine
July 19, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
July 17, 2023
From
Alnylam Pharmaceuticals
Via
Business Wire
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
June 30, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference
June 05, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
May 20, 2023
From
Alnylam
Via
Business Wire
Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity
May 04, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference
May 03, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Issues 2022 Corporate Responsibility Report
May 03, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
April 26, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
April 26, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Why Legend Biotech Stock Is Having Its Best Month Yet
April 25, 2023
With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high.
Via
MarketBeat
Alnylam to Webcast Conference Call Discussing First Quarter 2023 Financial Results
April 20, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Appointment of Peter Kellogg to Board of Directors
March 08, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
March 01, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity
February 23, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
February 21, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results
February 02, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates
January 08, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Updates to its Board of Directors
January 05, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes
December 21, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day
December 15, 2022
From
Alnylam Pharmaceuticals
Via
Business Wire
Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
December 08, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Virtual R&D Day
December 08, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.